Clinical efficacy of azithromycin-budesonide combination therapy in pediatric Mycoplasma pneumoniae pneumonia
Abstract
OBJECTIVE
To evaluate the clinical outcomes of adjunctive budesonide (BUD) therapy combined with azithromycin (AZM) in pediatric patients diagnosed with Mycoplasma pneumoniae pneumonia (MPP).
METHODS
This retrospective cohort analysis examined 120 pediatric MPP cases. Participants were stratified into either a control group (n=55, standard AZM treatment) or an observation group (n=65, AZM in combination with BUD) based on their treatment regimen. Comprehensive assessments included treatment efficacy, safety profiles, resolution of clinical manifestations, serum immunoglobulins, serum inflammatory markers, quality of life, and parental satisfaction. Additionally, univariate and multivariate logistic regression analyses were employed to identify independent predictors for therapeutic response.
RESULTS
The observation group exhibited a significantly superior clinical response rate, improved quality of life, and higher parental satisfaction than the control group, with no significant difference in adverse event incidence. Accelerated symptom resolution was observed in the observation group. Furthermore, significant immunomodulatory and anti-inflammatory effects were noted in the observation group. Univariate and multivariate analyses identified four independent predictors for treatment outcomes: disease duration (Odds Ratio [OR]=3.555, 95% Confidence Interval [CI]: 1.123-11.254), pre-treatment IgG levels (OR=0.280, 95% CI: 0.098-0.794), pre-treatment IL-6 levels (OR=3.848, 95%…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 65 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.